Abstract
The incidence of CMV infection in pediatric renal transplant recipients has increased as immunosuppression levels deepen following the use of newer immunosuppressive agents. It has been thought that 3–5 months of anti-CMV prophylaxis offers sufficient protection for these patients. We present a case of late-onset fatal CMV disease in a pediatric renal transplant recipient who received prolonged anti-CMV prophylaxis while on ”quadruple” immunosuppression with daclizumab, mycophenolate, tacrolimus, and prednisone. Our case has prompted us to reassess CMV surveillance, prophylaxis, and immunosuppression levels in our pediatric renal transplant patients.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 11 February 2000 / Revised: 19 July 2000 / Accepted: 27 July 2000
Rights and permissions
About this article
Cite this article
Tenney, F., Sakarcan, A. Fatal cytomegalovirus disease in a high-risk renal transplant recipient. Pediatr Nephrol 16, 8–10 (2001). https://doi.org/10.1007/s004670000475
Issue Date:
DOI: https://doi.org/10.1007/s004670000475